Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Praxis Precision Medicines (PRAX) Gains from Investment Securities: 2022-2025

Historic Gains from Investment Securities for Praxis Precision Medicines (PRAX) over the last 4 years, with Sep 2025 value amounting to $52,000.

  • Praxis Precision Medicines' Gains from Investment Securities rose 5100.00% to $52,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 814.74%. This contributed to the annual value of $308,000 for FY2024, which is 124.82% up from last year.
  • As of Q3 2025, Praxis Precision Medicines' Gains from Investment Securities stood at $52,000, which was up 126.09% from $23,000 recorded in Q2 2025.
  • Praxis Precision Medicines' Gains from Investment Securities' 5-year high stood at $1.2 million during Q1 2025, with a 5-year trough of $1,000 in Q3 2023.
  • Over the past 3 years, Praxis Precision Medicines' median Gains from Investment Securities value was $23,000 (recorded in 2025), while the average stood at $155,909.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first slumped by 85.71% in 2023, then surged by 5,100.00% in 2025.
  • Praxis Precision Medicines' Gains from Investment Securities (Quarterly) stood at $7,000 in 2022, then dropped by 28.57% to $5,000 in 2023, then surged by 3,040.00% to $157,000 in 2024, then spiked by 5,100.00% to $52,000 in 2025.
  • Its last three reported values are $52,000 in Q3 2025, $23,000 for Q2 2025, and $1.2 million during Q1 2025.